GO:0002435 immune complex clearance by erythrocytes: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002435 describes the biological process in which erythrocytes bind complement-coated immune complexes via complement receptor 1 (CR1) and transport them to the liver or spleen for removal by phagocytes.
• CR1 (CD35) on the erythrocyte surface is the central receptor that mediates immune adherence and subsequent clearance of complement-opsonized immune complexes.
• Defective erythrocyte immune complex clearance is linked to autoimmune diseases such as systemic lupus erythematosus (SLE), where reduced CR1 expression or function contributes to disease pathogenesis.
• The process is conserved in mice, where erythrocyte CR1 mediates clearance of Streptococcus pneumoniae by immune adherence, providing a tractable model for mechanistic studies.
• Experimental modulation of erythrocyte immune complex binding can be achieved through immunocamouflage (PEG-grafting) or cytokine stimulation such as TNF-alpha, offering tools to study the process.
• Research on GO:0002435 employs methods such as immune adherence assays, flow cytometry, and knockout mouse models to dissect the molecular players and therapeutic potential.
Description
Immune complex clearance by erythrocytes (GO:0002435) is a vital biological process that prevents the accumulation of circulating immune complexes, which can otherwise deposit in tissues and trigger inflammation. The process begins when complement receptor 1 (CR1, CD35) on the erythrocyte surface binds to complement-coated immune complexes, a phenomenon known as immune adherence. This binding allows erythrocytes to act as shuttles, transporting the complexes to the liver and spleen, where they are transferred to phagocytes and removed from circulation. The importance of this process is underscored by its role in autoimmune diseases; impaired erythrocyte CR1 function is associated with systemic lupus erythematosus (SLE) and other conditions characterized by defective immune complex clearance. Understanding GO:0002435 is therefore critical for researchers studying autoimmunity, infectious diseases, and complement biology. The process also intersects with pathogen immune evasion, as seen with hepatitis C virus (HCV), which can bind to erythrocytes via complement, potentially altering clearance dynamics. Moreover, animal models have demonstrated that erythrocyte CR1 can mediate clearance of pathogens such as Streptococcus pneumoniae, highlighting its broader immunological significance.
immune complex clearance by erythrocytes At A Glance
| GO ID | GO:0002435 |
|---|---|
| GO term | immune complex clearance by erythrocytes |
| Ontology | biological_process |
| Synonym | immune complex clearance by RBCs, immune complex clearance by red blood cells |
| Major function | Binding and transport of complement-coated immune complexes to liver/spleen for phagocytic removal |
| Key receptor | Complement receptor 1 (CR1, CD35) |
| Cellular location | Erythrocyte membrane surface |
| Physiological outcome | Prevention of immune complex deposition and tissue damage |
| Associated diseases | Systemic lupus erythematosus (SLE), cryoglobulinemia, hepatitis C virus infection |
What Is GO:0002435?
GO:0002435, immune complex clearance by erythrocytes, is defined as the process in which erythrocytes bind complement-coated immune complexes via complement receptor 1 (CR1) and transport them to the liver or spleen for presentation to phagocytes. The process concludes when the immune complex is removed from CR1, allowing the erythrocyte to re-enter general circulation.
Why Is immune complex clearance by erythrocytes Important in Cell Biology?
GO:0002435 is essential for maintaining immune homeostasis by preventing the harmful accumulation of circulating immune complexes. Defects in this process are directly implicated in the pathogenesis of autoimmune diseases such as SLE, where reduced erythrocyte CR1 levels correlate with disease activity. Furthermore, the process is exploited or evaded by pathogens like HCV, making it a focal point for infectious disease research. Understanding the molecular mechanisms of immune complex clearance by erythrocytes can inform therapeutic strategies to enhance clearance in autoimmune conditions or to modulate it in infections.
• Prevents immune complex deposition in tissues, which can cause inflammation and organ damage.
• Reduced erythrocyte CR1 expression is linked to SLE pathogenesis and disease flares.
• Erythrocyte CR1 mediates clearance of pathogens such as Streptococcus pneumoniae via immune adherence.
• HCV can bind to erythrocytes via complement, potentially interfering with normal clearance mechanisms.
• Cryoglobulinemia, characterized by abnormal immune complexes, may involve altered erythrocyte clearance.
• TNF-alpha enhances immune complex clearance in murine models, suggesting cytokine regulation.
• Immunocamouflaged erythrocytes show altered immune complex binding, providing a tool to study CR1 function.
• The process is a potential therapeutic target for modulating immune complex diseases.
• Animal models (e.g., mice) allow genetic dissection of CR1 and complement components.
• Studying this process aids in understanding complement-mediated immunity and autoimmunity.
What Happens During immune complex clearance by erythrocytes?
Complement Opsonization of Immune Complexes
In simple terms: Immune complexes are tagged with complement proteins, marking them for binding to erythrocytes.
The process begins when circulating immune complexes activate the complement system, leading to the deposition of complement fragments such as C3b on the complex. This opsonization is a prerequisite for recognition by complement receptor 1 (CR1) on erythrocytes. The complement-coated immune complexes are then available for binding to CR1.
Binding to Erythrocyte CR1 (Immune Adherence)
In simple terms: Erythrocytes grab the tagged immune complexes using their CR1 receptors.
CR1 (CD35) on the erythrocyte surface binds to the complement-coated immune complexes, a phenomenon known as immune adherence. This binding is specific and reversible, allowing erythrocytes to capture complexes without internalizing them. The interaction is critical for subsequent transport.
Transport to Liver and Spleen
In simple terms: The erythrocyte carries the immune complex to the liver or spleen.
Once bound, erythrocytes transport the immune complexes to the liver and spleen, where the sinusoidal vasculature allows interaction with resident phagocytes. This shuttling mechanism efficiently concentrates immune complexes in organs specialized for clearance.
Transfer to Phagocytes and Removal
In simple terms: Liver and spleen macrophages take the immune complex from the erythrocyte and destroy it.
In the liver and spleen, phagocytes (e.g., Kupffer cells) recognize and remove the immune complexes from erythrocyte CR1. The erythrocyte, now free of the complex, returns to circulation. This transfer is mediated by complement receptors on phagocytes and may involve additional opsonins.
Regulation by Cytokines and CR1 Expression
In simple terms: Cytokines like TNF-alpha can boost this clearance process.
The efficiency of immune complex clearance by erythrocytes can be modulated by cytokines. In a murine model, TNF-alpha enhanced immune complex clearance, suggesting a regulatory role. Additionally, CR1 expression levels on erythrocytes influence clearance capacity, and reduced CR1 is associated with impaired clearance in SLE.
Key Genes Involved in GO:0002435 immune complex clearance by erythrocytes
The following genes and proteins are central to the process of immune complex clearance by erythrocytes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CR1 | Complement receptor 1; binds complement-coated immune complexes on erythrocytes | Central mediator of immune adherence; reduced expression in SLE |
| C3 | Complement component 3; opsonizes immune complexes with C3b | Essential for CR1 binding; knockout models available |
| C4 | Complement component 4; involved in classical pathway activation | Contributes to immune complex opsonization |
| C1Q | Complement component 1q; initiates classical pathway | Deficiency linked to autoimmune complex diseases |
| FCGR2B | Inhibitory Fc gamma receptor; regulates phagocyte activity | Modulates clearance and autoimmunity |
| CR3 (ITGAM) | Complement receptor 3 on phagocytes; mediates removal of complexes | Facilitates transfer from erythrocytes to phagocytes |
| TNF | Pro-inflammatory cytokine; enhances immune complex clearance | Shown to boost clearance in murine models |
| CRP | C-reactive protein; binds immune complexes and complement | May influence clearance pathways |
| SERPING1 | C1 inhibitor; regulates complement activation | Deficiency causes hereditary angioedema with immune complex issues |
| CD55 | Decay-accelerating factor; protects erythrocytes from complement lysis | Regulates complement on erythrocyte surface |
| CD59 | Protectin; inhibits complement membrane attack complex | Prevents erythrocyte lysis during clearance |
| CR2 (CD21) | Complement receptor 2; binds C3d on immune complexes | Modulates B cell responses to complexes |
| C5 | Complement component 5; involved in terminal pathway | Therapeutic target in complement-mediated diseases |
| C1QA | Subunit of C1q; initiates classical complement | Genetic deficiency linked to SLE |
| C1QB | Subunit of C1q; initiates classical complement | Genetic deficiency linked to SLE |
| C1QC | Subunit of C1q; initiates classical complement | Genetic deficiency linked to SLE |
| C2 | Complement component 2; classical pathway | Polymorphisms associated with autoimmune diseases |
| C4A | Complement component 4A; opsonization | Copy number variation affects clearance |
How Is immune complex clearance by erythrocytes Regulated?
The process of immune complex clearance by erythrocytes is regulated at multiple levels. CR1 expression on erythrocytes is a key determinant of clearance capacity, and its levels can be modulated by cytokines and disease states. In a murine model, TNF-alpha administration enhanced immune complex clearance, indicating positive regulation by pro-inflammatory cytokines. Additionally, complement regulatory proteins such as CD55 and CD59 protect erythrocytes from complement-mediated lysis during the clearance process, ensuring the erythrocyte survives to return to circulation. The availability of complement components for opsonization also influences the rate of clearance, as deficiencies in classical pathway components can impair immune complex handling.
immune complex clearance by erythrocytes and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CR1 | Systemic lupus erythematosus (SLE) | CR1 knockout mouse; humanized mouse models |
| CR1 | Streptococcus pneumoniae infection | Mouse infection models with CR1 variants |
| C3 | Complement deficiencies and autoimmune diseases | C3 knockout mice |
| TNF | Inflammatory regulation of clearance | TNF knockout or transgenic mice |
| CRP | Cardiovascular and autoimmune inflammation | CRP transgenic mice |
Systemic Lupus Erythematosus (SLE)
SLE is characterized by defective clearance of immune complexes, leading to their deposition in tissues and subsequent inflammation. Reduced expression or function of erythrocyte CR1 is a well-documented feature in SLE patients, contributing to impaired clearance. This defect is thought to play a role in disease pathogenesis and flares, making CR1 a potential biomarker and therapeutic target.
Cryoglobulinemia
Cryoglobulinemia involves abnormal immunoglobulins that form immune complexes, which can deposit in small vessels and cause vasculitis. The clearance of these complexes by erythrocytes may be overwhelmed or impaired, contributing to disease manifestations. Research into erythrocyte CR1 function in cryoglobulinemia could elucidate mechanisms of complex deposition.
Hepatitis C Virus (HCV) Infection
HCV can bind to erythrocytes via complement, potentially hijacking the immune adherence pathway. This interaction may alter the normal clearance of immune complexes and facilitate viral dissemination or immune evasion. Understanding how HCV interacts with erythrocyte CR1 could inform antiviral strategies.
Streptococcus pneumoniae Infection
Erythrocyte CR1 mediates the clearance of Streptococcus pneumoniae by immune adherence, as shown in mouse models. This highlights the role of erythrocytes in host defense against encapsulated bacteria and suggests that defects in this pathway could increase susceptibility to certain infections.
From immune complex clearance by erythrocytes-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does CR1 knockout impair immune complex clearance? | CR1 knockout mouse |
| Does a point mutation in CR1 affect ligand binding? | CR1 point-mutation knock-in mouse |
| Can human CR1 be studied in vivo? | CR1 humanized knock-in mouse |
| Where is CR1 localized on erythrocytes? | CR1 tagged knock-in (e.g., GFP) mouse |
| Does CR1 overexpression enhance clearance? | CR1 overexpression transgenic mouse |
| What is the effect of TNF-alpha on clearance? | TNF knockout or transgenic mouse |
How to Study the immune complex clearance by erythrocytes Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Immune adherence assay | Binding of complement-coated complexes to erythrocytes | Assessing CR1 function in patient samples |
| Flow cytometry | CR1 surface expression and complex binding | Correlating CR1 levels with disease activity |
| ELISA | Circulating immune complex levels | Monitoring disease activity in SLE |
| Mouse knockout models | In vivo clearance and host defense | Testing CR1 requirement in clearance |
| Immunocamouflage (PEGylation) | Effect of surface modification on complex binding | Studying CR1 accessibility |
| Cytokine stimulation assays | Modulation of clearance by TNF-alpha | Investigating regulatory mechanisms |
| Confocal microscopy | Localization of complexes and CR1 on erythrocytes | Visualizing immune adherence |
| CRISPR screening | Identification of genes affecting clearance | High-throughput discovery of novel regulators |
Immune Adherence Assays
Immune adherence assays measure the binding of complement-coated immune complexes to erythrocytes. These assays typically use radiolabeled or fluorescently labeled complexes and quantify binding to erythrocytes from patients or animal models. They are fundamental for assessing CR1 function and clearance capacity.
Flow Cytometry for CR1 Expression
Flow cytometry using anti-CR1 antibodies allows quantification of CR1 surface expression on erythrocytes. This method is used to correlate CR1 levels with disease activity in SLE and other conditions. It can also assess binding of immune complexes to erythrocytes.
Animal Models and Knockouts
Mouse models, including CR1 knockout and transgenic lines, are invaluable for studying immune complex clearance in vivo. For example, CR1 on mouse erythrocytes mediates clearance of Streptococcus pneumoniae, and knockout mice can reveal the contribution of CR1 to host defense. TNF-alpha enhancement of clearance has also been demonstrated in murine models.
Immunocamouflage and PEGylation
Immunocamouflage by poly(ethylene glycol) grafting onto erythrocytes can modulate immune complex binding. This technique has been used to study the accessibility of CR1 and its interaction with immune complexes. It provides a tool to dissect the molecular requirements for binding.
How CRISPR Can Be Used to Study GO:0002435 immune complex clearance by erythrocytes
Knockout
CRISPR knockout of CR1 or complement components (e.g., C3) in cell lines or animal models can abolish immune complex clearance, providing definitive evidence of their necessity. For example, CR1 knockout mice show impaired clearance of Streptococcus pneumoniae. Such models are essential for validating the role of specific genes in GO:0002435.
Point Mutation
Introducing point mutations in CR1 or complement proteins can dissect structure-function relationships. For instance, mutations in the ligand-binding domain of CR1 can abrogate immune adherence without affecting surface expression. These models help identify critical residues for complement binding.
Knock-in
Knock-in of human CR1 into mouse models (humanization) allows study of human-specific aspects of immune complex clearance. Tagged knock-in (e.g., GFP-CR1) enables real-time tracking of receptor localization and trafficking during clearance.
Overexpression
Overexpression of CR1 or complement regulators (e.g., CD55) can enhance or modulate clearance. Transgenic mice overexpressing CR1 may show accelerated clearance, useful for testing therapeutic strategies. Overexpression in cell lines can also facilitate biochemical studies of CR1-ligand interactions.
How EDITGENE Supports immune complex clearance by erythrocytes Research
Researchers studying immune complex clearance by erythrocytes-related genes often need to determine whether a candidate gene is causally involved in the process or merely correlated with it. This requires precise genetic manipulation, which is where EDITGENE's CRISPR services can accelerate discovery.
Contact EDITGENE today to design your custom CRISPR model for immune complex clearance by erythrocytes research.
Frequently Asked Questions About immune complex clearance by erythrocytes
What is GO:0002435?
GO:0002435 is the Gene Ontology term for immune complex clearance by erythrocytes, the process where red blood cells bind complement-coated immune complexes via CR1 and transport them to the liver or spleen for removal.
What genes are involved in immune complex clearance by erythrocytes?
Key genes include CR1 (complement receptor 1), C3, C4, C1Q, and FCGR2B, among others.
How does CR1 mediate immune complex clearance?
CR1 on erythrocytes binds complement-coated immune complexes, allowing their transport to the liver and spleen where phagocytes remove them.
What diseases are associated with defective immune complex clearance by erythrocytes?
Systemic lupus erythematosus (SLE), cryoglobulinemia, and hepatitis C virus infection are associated with impaired clearance.
Can immune complex clearance by erythrocytes be studied in mice?
Yes, mouse models have been used to study CR1-mediated clearance of Streptococcus pneumoniae and the effect of TNF-alpha.
What methods are used to study immune complex clearance by erythrocytes?
Common methods include immune adherence assays, flow cytometry, ELISA, and knockout mouse models.
How is CR1 expression regulated on erythrocytes?
CR1 expression can be modulated by cytokines and is reduced in autoimmune diseases like SLE.
What is the role of complement in immune complex clearance by erythrocytes?
Complement opsonizes immune complexes with C3b, which is recognized by CR1 on erythrocytes, initiating the clearance process.
Can CRISPR be used to study immune complex clearance by erythrocytes?
Yes, CRISPR knockout, knock-in, and overexpression models can dissect the function of CR1 and other genes in this process.
Why is immune complex clearance by erythrocytes important?
It prevents the deposition of immune complexes in tissues, which can cause inflammation and organ damage, and is crucial for immune homeostasis.
Conclusion
GO:0002435, immune complex clearance by erythrocytes, is a critical biological process that safeguards against immune complex-mediated pathology. The central role of CR1 and complement components, along with links to diseases like SLE and infections, makes it a vibrant area of research. Advances in CRISPR technology and animal models continue to unravel the molecular details, offering hope for novel therapies.
References
- 2. Kavai M et al.. 2007. Immune complex clearance by monocytes and macrophages in systemic lupus erythematosus.. Autoimmun Rev 6(7):497-502 PMID: 17643939
- 3. Kavai M. 2008. Immune complex clearance by complement receptor type 1 in SLE.. Autoimmun Rev 8(2):160-4 PMID: 18602499
- 4. Li J et al.. 2010. Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence.. Infect Immun 78(7):3129-35 PMID: 20439480
- 5. Bradley AJ et al.. 2007. Immune complex binding by immunocamouflaged [poly(ethylene glycol)-grafted] erythrocytes.. Am J Hematol 82(11):970-5 PMID: 17654505
- 6. Salam KA et al.. 2018. Binding of Free and Immune Complex-Associated Hepatitis C Virus to Erythrocytes Is Mediated by the Complement System.. Hepatology 68(6):2118-2129 PMID: 29742812
- 7. Madi N et al.. 1990. [Cryoglobulinemia type II].. Nephrologie 11(4):237-41 PMID: 2074925
- 8. Alves-Rosa MF et al.. 1998. Enhancement of immune complex clearance by TNF-alpha in a murine model.. Clin Immunol Immunopathol 89(3):214-21 PMID: 9837691
